References

1. Itoh K, Nakamura K, Iijima M, Sesaki H. Mitochondrial Dynamics in

Neurodegeneration. Trends in Cell Biology. 2013; 23(2): 64-71. doi:
10.1016/j.tcb.2012.10.006.
2. Mega M, Lee L, Dinov I, Mishkin F, Toga A, Cummings J. Cerebral Correlates of
Psychotic Symptoms in Alzheimers Disease. Journal of Neurology, Neurosurgery &
Psychiatry. 2000; 69(2): 167-171. doi: 10.1136/jnnp.69.2.167.
3. Tsolaki M, Kokarida K, Iakovidou V, Stilopoulos E, Meimaris J, Kazis A.
Extrapyramidal Signs and Symptoms in Alzheimers Disease: Prevalence and
Correlation with The First Symptom. American Journal of Alzheimers Disease and
Other Dementias. 2001; 16(5): 268-278. doi: 10.1177/153331750101600512.
4. Krajewski, KM, Lewis, RA, Fuerst, Dr, et al. Neurological Dysfunction and Axonal
Degeneration in CharcotMarieTooth Disease Type 1A. Brain. 2000; 123 (7): 15161527. doi: http://dx.doi.org/10.1093/brain/123.7.1516
5. Cordeiro J, Marques W, Hallack JEC, Osrio FL. Charcot-Marie-Tooth Disease,
Psychiatric Indicators and Quality of Life: A Systematic Review. ASN Neuro. 2014;
6(3): e00145. doi: 10.1042/AN20130048.
6. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife Vascular Risk Factors and
Alzheimers Disease in Later Life: Longitudinal, Population Based Study. British
Medical Journal. 2001; 322: 1447-14451.
doi: http://dx.doi.org/10.1136/bmj.322.7300.1447.
7. Solomon A, Mangialasche F, Richard E, et al. Advances in the Prevention of
Alzheimers Disease and Dementia. Journal of Internal Medicine. 2014; 275(3): 229250. doi: 10.1111/joim.12178.

Yorki 2
8. Albert MS, DeKosky ST, Dickson D, et al. The Diagnosis of Mild Cognitive
Impairment due to Alzheimers Disease: Recommendations from the National
Institute on Aging- Alzheimers Association Workgroups On Diagnostic Guidelines
for Alzheimers Disease. Alzheimers & Dementia. 2011; 7(3): 270-279. doi:
10.1016/j.jalz.2011.03.008.
9. Hammond N, Wang Y, Dimachkie M, Barohn R. Nutritional Neuropathies.
Neurology Clinics. 2013; 31(2): 477-489. doi : 10.1016/j.ncl.2013.02.002.
10. Li X, Zi X, Li L, et al. Rapid Genetic Screening of Charcot-Marie-Tooth Disease
Type 1A and Hereditary Neuropathy with Liability to Pressure Palsies Patients.
Neural Regeneration Research. 2012; 7(32): 2522-2527. doi: 10.3969/j.issn.16735374.2012.32.006.
11. Bajic V, Milovanovic ES, Spremo-Potparevic B, et al. Treatments of Alzheimers
disease: Classical Therapeutic Approach. Current Pharmaceutical Analysis. 2016;
12(2): 82-90. doi: 10.2174/1573412911666150611184740.
12. Cummings JL. Cholinesterase Inhibitors: A New Class of Psychotropic Compounds.
American Journal of Psychiatry. 2000; 157: 4-15. doi:
http://dx.doi.org/10.1176/ajp.157.1.4.
13. Cummings JL. Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based
Recommendations. American Journal of Geriatric Psychiatry. 2003; 11(2): 131-145.
doi: http://dx.doi.org/10.1097/00019442-200303000-00004.
14. Schenone A, Nobbio L, Bragadin MM, Ursino G, Grandis M. Inherited Neuropathies.
Current Treatment Options in Neurology. 2011; 13: 160-179. doi: 10.1007/s11940011-0115-z.

Yorki 3
15. Ballatore C, Brunden K, Huryn DM, Trojanowski JQ, Lee V, Smith AB. Microtubule
Stabilizing Agents as Potential Treatment for Alzheimers Disease and Related
Neurodegenerative Tauopathies. Journal of Medical Chemistry. 2012; 55(21): 89798996. doi: 10.1021/jm301079z.